论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
临床前癌症免疫治疗中新兴的纳米技术:推动临床应用
Authors Pan X, Han T, Zhao Z , Wang X, Fang X
Received 29 February 2024
Accepted for publication 16 June 2024
Published 2 July 2024 Volume 2024:19 Pages 6619—6641
DOI https://doi.org/10.2147/IJN.S466459
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Dongwoo Khang
Xuan Pan,1,* Ting Han,2,* Zixuan Zhao,3,4 Xiaoming Wang,1 Xiaosan Fang1
1Department of Hepato-Biliary-Pancreatic Surgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, 241000, People’s Republic of China; 2Department of Gastroenterology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, 241000, People’s Republic of China; 3The Translational Research Institute for Neurological Disorders of Department of Neurosurgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, 241000, People’s Republic of China; 4The Institute of Brain Science, Wannan Medical College, Wuhu, 241000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiaosan Fang; Xiaoming Wang, Department of Hepato-Biliary-Pancreatic Surgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), 2 West Zheshan Road, Wuhu, 241002, People’s Republic of China, Tel +86-0553-5739219, Email 20142031@wnmc.edu.cn; wxm6901@126.com
Abstract: The high malignant degree and poor prognosis of pancreatic cancer (PC) pose severe challenges to the basic research and clinical translation of next-generation therapies. The rise of immunotherapy has improved the treatment of a variety of solid tumors, while the application in PC is highly restricted by the challenge of immunosuppressive tumor microenvironment. The latest progress of nanotechnology as drug delivery platform and immune adjuvant has improved drug delivery in a variety of disease backgrounds and enhanced tumor therapy based on immunotherapy. Based on the immune loop of PC and the status quo of clinical immunotherapy of tumors, this article discussed and critically analyzed the key transformation difficulties of immunotherapy adaptation to the treatment of PC, and then proposed the rational design strategies of new nanocarriers for drug delivery and immune regulation, especially the design of combined immunotherapy. This review also put forward prospective views on future research directions, so as to provide information for the new means of clinical treatment of PC combined with the next generation of nanotechnology and immunotherapy.
Keywords: pancreatic cancer, immunotherapy, nanomedicine, immunosuppressive tumor microenvironment regulation, combined drug delivery strategy